Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Self-assembly Stability Compromises the Efficacy of Tryptophan-Containing Designed Anti-measles Virus Peptides.

Mendonça DA, Figueira TN, Melo MN, Harder O, Niewiesk S, Moscona A, Porotto M, Veiga AS.

J Nanomed Nanotechnol. 2019;10(2). pii: 528. doi: 10.35248/2157-7439.19.10.528. Epub 2019 Mar 12.

2.

Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent.

Outlaw VK, Bottom-Tanzer S, Kreitler DF, Gellman SH, Porotto M, Moscona A.

J Am Chem Soc. 2019 Aug 14;141(32):12648-12656. doi: 10.1021/jacs.9b04615. Epub 2019 Aug 5.

PMID:
31268705
3.

Authentic Modeling of Human Respiratory Virus Infection in Human Pluripotent Stem Cell-Derived Lung Organoids.

Porotto M, Ferren M, Chen YW, Siu Y, Makhsous N, Rima B, Briese T, Greninger AL, Snoeck HW, Moscona A.

MBio. 2019 May 7;10(3). pii: e00723-19. doi: 10.1128/mBio.00723-19.

4.

Inhibiting Human Parainfluenza Virus Infection by Preactivating the Cell Entry Mechanism.

Bottom-Tanzer SF, Rybkina K, Bell JN, Alabi CA, Mathieu C, Lu M, Biswas S, Vasquez M, Porotto M, Melero JA, Más V, Moscona A.

MBio. 2019 Feb 19;10(1). pii: e02900-18. doi: 10.1128/mBio.02900-18.

5.

Measles Virus Bearing Measles Inclusion Body Encephalitis-Derived Fusion Protein Is Pathogenic after Infection via the Respiratory Route.

Mathieu C, Ferren M, Jurgens E, Dumont C, Rybkina K, Harder O, Stelitano D, Madeddu S, Sanna G, Schwartz D, Biswas S, Hardie D, Hashiguchi T, Moscona A, Horvat B, Niewiesk S, Porotto M.

J Virol. 2019 Apr 3;93(8). pii: e01862-18. doi: 10.1128/JVI.01862-18. Print 2019 Apr 15.

6.

Analysis of a Subacute Sclerosing Panencephalitis Genotype B3 Virus from the 2009-2010 South African Measles Epidemic Shows That Hyperfusogenic F Proteins Contribute to Measles Virus Infection in the Brain.

Angius F, Smuts H, Rybkina K, Stelitano D, Eley B, Wilmshurst J, Ferren M, Lalande A, Mathieu C, Moscona A, Horvat B, Hashiguchi T, Porotto M, Hardie D.

J Virol. 2019 Feb 5;93(4). pii: e01700-18. doi: 10.1128/JVI.01700-18. Print 2019 Feb 15.

7.

Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles.

Figueira TN, Mendonça DA, Gaspar D, Melo MN, Moscona A, Porotto M, Castanho MARB, Veiga AS.

ACS Nano. 2018 Oct 23;12(10):9855-9865. doi: 10.1021/acsnano.8b01422. Epub 2018 Sep 24.

8.

Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane.

Figueira TN, Augusto MT, Rybkina K, Stelitano D, Noval MG, Harder OE, Veiga AS, Huey D, Alabi CA, Biswas S, Niewiesk S, Moscona A, Santos NC, Castanho MARB, Porotto M.

Bioconjug Chem. 2018 Oct 17;29(10):3362-3376. doi: 10.1021/acs.bioconjchem.8b00527. Epub 2018 Sep 14.

9.

Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation.

Iketani S, Shean RC, Ferren M, Makhsous N, Aquino DB, des Georges A, Rima B, Mathieu C, Porotto M, Moscona A, Greninger AL.

MBio. 2018 Jul 3;9(4). pii: e00898-18. doi: 10.1128/mBio.00898-18.

10.

Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates.

Mathieu C, Porotto M, Figueira TN, Horvat B, Moscona A.

J Infect Dis. 2018 Jun 20;218(2):218-227. doi: 10.1093/infdis/jiy152.

11.

Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length.

Augusto MT, Hollmann A, Porotto M, Moscona A, Santos NC.

Molecules. 2017 Jul 15;22(7). pii: E1190. doi: 10.3390/molecules22071190.

12.

A three-dimensional model of human lung development and disease from pluripotent stem cells.

Chen YW, Huang SX, de Carvalho ALRT, Ho SH, Islam MN, Volpi S, Notarangelo LD, Ciancanelli M, Casanova JL, Bhattacharya J, Liang AF, Palermo LM, Porotto M, Moscona A, Snoeck HW.

Nat Cell Biol. 2017 May;19(5):542-549. doi: 10.1038/ncb3510. Epub 2017 Apr 24.

13.

Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance.

Figueira TN, Freire JM, Cunha-Santos C, Heras M, Gonçalves J, Moscona A, Porotto M, Salomé Veiga A, Castanho MA.

Sci Rep. 2017 Mar 30;7:45647. doi: 10.1038/srep45647.

14.

Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides.

Mathieu C, Augusto MT, Niewiesk S, Horvat B, Palermo LM, Sanna G, Madeddu S, Huey D, Castanho MA, Porotto M, Santos NC, Moscona A.

Sci Rep. 2017 Mar 8;7:43610. doi: 10.1038/srep43610.

15.

In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Figueira TN, Palermo LM, Veiga AS, Huey D, Alabi CA, Santos NC, Welsch JC, Mathieu C, Horvat B, Niewiesk S, Moscona A, Castanho MARB, Porotto M.

J Virol. 2016 Dec 16;91(1). pii: e01554-16. doi: 10.1128/JVI.01554-16. Print 2017 Jan 1.

16.

Features of Circulating Parainfluenza Virus Required for Growth in Human Airway.

Palermo LM, Uppal M, Skrabanek L, Zumbo P, Germer S, Toussaint NC, Rima BK, Huey D, Niewiesk S, Porotto M, Moscona A.

MBio. 2016 Mar 15;7(2):e00235. doi: 10.1128/mBio.00235-16.

17.

Erratum for Gui et al., Electron Tomography Imaging of Surface Glycoproteins on Human Parainfluenza Virus 3: Association of Receptor Binding and Fusion Proteins before Receptor Engagement.

Gui L, Jurgens E, Ebner JL, Porotto M, Moscona A, Lee KK.

MBio. 2016 Jan 19;7(1):e01928-15. doi: 10.1128/mBio.01928-15. No abstract available.

18.

RSV vaccine: Beating the virus at its own game.

Moscona A.

Sci Transl Med. 2015 Nov 4;7(312):312fs44. doi: 10.1126/scitranslmed.aad2515.

PMID:
26537253
19.
20.

Measles fusion machinery is dysregulated in neuropathogenic variants.

Jurgens EM, Mathieu C, Palermo LM, Hardie D, Horvat B, Moscona A, Porotto M.

MBio. 2015 Feb 10;6(1). pii: e02528-14. doi: 10.1128/mBio.02528-14.

21.

Unity in diversity: shared mechanism of entry among paramyxoviruses.

Palgen JL, Jurgens EM, Moscona A, Porotto M, Palermo LM.

Prog Mol Biol Transl Sci. 2015;129:1-32. doi: 10.1016/bs.pmbts.2014.10.001. Epub 2014 Dec 1. Review.

22.

Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.

Mathieu C, Huey D, Jurgens E, Welsch JC, DeVito I, Talekar A, Horvat B, Niewiesk S, Moscona A, Porotto M.

J Virol. 2015 Jan 15;89(2):1143-55. doi: 10.1128/JVI.02417-14. Epub 2014 Nov 5.

23.

Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection.

Palmer SG, DeVito I, Jenkins SG, Niewiesk S, Porotto M, Moscona A.

J Virol. 2014 Nov;88(22):13495-502. doi: 10.1128/JVI.01965-14. Epub 2014 Sep 10.

24.

Interaction between the hemagglutinin-neuraminidase and fusion glycoproteins of human parainfluenza virus type III regulates viral growth in vivo.

Xu R, Palmer SG, Porotto M, Palermo LM, Niewiesk S, Wilson IA, Moscona A.

MBio. 2013 Oct 22;4(5):e00803-13. doi: 10.1128/mBio.00803-13.

25.

Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Welsch JC, Talekar A, Mathieu C, Pessi A, Moscona A, Horvat B, Porotto M.

J Virol. 2013 Dec;87(24):13785-94. doi: 10.1128/JVI.02436-13. Epub 2013 Oct 9.

26.

Measles virus fusion machinery activated by sialic acid binding globular domain.

Talekar A, Moscona A, Porotto M.

J Virol. 2013 Dec;87(24):13619-27. doi: 10.1128/JVI.02256-13. Epub 2013 Oct 9.

27.

Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation.

Talekar A, DeVito I, Salah Z, Palmer SG, Chattopadhyay A, Rose JK, Xu R, Wilson IA, Moscona A, Porotto M.

J Virol. 2013 Oct;87(20):10980-96. doi: 10.1128/JVI.01646-13. Epub 2013 Jul 31.

28.

Regulation of paramyxovirus fusion activation: the hemagglutinin-neuraminidase protein stabilizes the fusion protein in a pretriggered state.

Porotto M, Salah ZW, Gui L, DeVito I, Jurgens EM, Lu H, Yokoyama CC, Palermo LM, Lee KK, Moscona A.

J Virol. 2012 Dec;86(23):12838-48. doi: 10.1128/JVI.01965-12. Epub 2012 Sep 19.

29.

Adaptation of human parainfluenza virus to airway epithelium reveals fusion properties required for growth in host tissue.

Palmer SG, Porotto M, Palermo LM, Cunha LF, Greengard O, Moscona A.

MBio. 2012 Jun 5;3(3). pii: e00137-12. doi: 10.1128/mBio.00137-12. Print 2012.

30.

A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity.

Pessi A, Langella A, Capitò E, Ghezzi S, Vicenzi E, Poli G, Ketas T, Mathieu C, Cortese R, Horvat B, Moscona A, Porotto M.

PLoS One. 2012;7(5):e36833. doi: 10.1371/journal.pone.0036833. Epub 2012 May 16.

31.

Bronchiolitis: too-familiar yet too-mysterious disease of childhood.

DeLaMora P, Moscona A.

Arch Pediatr Adolesc Med. 2012 Aug;166(8):769-70. No abstract available.

PMID:
22473888
32.

The second receptor binding site of the globular head of the Newcastle disease virus hemagglutinin-neuraminidase activates the stalk of multiple paramyxovirus receptor binding proteins to trigger fusion.

Porotto M, Salah Z, DeVito I, Talekar A, Palmer SG, Xu R, Wilson IA, Moscona A.

J Virol. 2012 May;86(10):5730-41. doi: 10.1128/JVI.06793-11. Epub 2012 Mar 21.

33.

Rapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainment.

Talekar A, Pessi A, Glickman F, Sengupta U, Briese T, Whitt MA, Mathieu C, Horvat B, Moscona A, Porotto M.

PLoS One. 2012;7(3):e30538. doi: 10.1371/journal.pone.0030538. Epub 2012 Mar 2.

34.

Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.

Porotto M, Palmer SG, Palermo LM, Moscona A.

J Biol Chem. 2012 Jan 2;287(1):778-93. doi: 10.1074/jbc.M111.298059. Epub 2011 Nov 22.

35.

Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus.

Lee KK, Pessi A, Gui L, Santoprete A, Talekar A, Moscona A, Porotto M.

J Biol Chem. 2011 Dec 9;286(49):42141-9. doi: 10.1074/jbc.M111.254243. Epub 2011 Oct 12.

36.

Spring-loaded model revisited: paramyxovirus fusion requires engagement of a receptor binding protein beyond initial triggering of the fusion protein.

Porotto M, Devito I, Palmer SG, Jurgens EM, Yee JL, Yokoyama CC, Pessi A, Moscona A.

J Virol. 2011 Dec;85(24):12867-80. doi: 10.1128/JVI.05873-11. Epub 2011 Oct 5.

37.

Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Farzan SF, Palermo LM, Yokoyama CC, Orefice G, Fornabaio M, Sarkar A, Kellogg GE, Greengard O, Porotto M, Moscona A.

J Biol Chem. 2011 Nov 4;286(44):37945-54. doi: 10.1074/jbc.M111.256248. Epub 2011 Jul 28.

38.

Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus.

Porotto M, Yi F, Moscona A, LaVan DA.

PLoS One. 2011 Mar 1;6(3):e16874. doi: 10.1371/journal.pone.0016874.

39.

Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry.

Porotto M, Rockx B, Yokoyama CC, Talekar A, Devito I, Palermo LM, Liu J, Cortese R, Lu M, Feldmann H, Pessi A, Moscona A.

PLoS Pathog. 2010 Oct 28;6(10):e1001168. doi: 10.1371/journal.ppat.1001168.

40.

A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G, Li QX, Wurtman D, Niewiesk S, Fang F.

J Infect Dis. 2010 Jul 15;202(2):234-41. doi: 10.1086/653621.

41.

Viral entry inhibitors targeted to the membrane site of action.

Porotto M, Yokoyama CC, Palermo LM, Mungall B, Aljofan M, Cortese R, Pessi A, Moscona A.

J Virol. 2010 Jul;84(13):6760-8. doi: 10.1128/JVI.00135-10. Epub 2010 Mar 31.

42.

A broad-spectrum antiviral targeting entry of enveloped viruses.

Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3157-62. doi: 10.1073/pnas.0909587107. Epub 2010 Jan 28.

43.

Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro.

Aljofan M, Sganga ML, Lo MK, Rootes CL, Porotto M, Meyer AG, Saubern S, Moscona A, Mungall BA.

Virol J. 2009 Nov 4;6:187. doi: 10.1186/1743-422X-6-187.

44.

Human parainfluenza virus infection of the airway epithelium: viral hemagglutinin-neuraminidase regulates fusion protein activation and modulates infectivity.

Palermo LM, Porotto M, Yokoyama CC, Palmer SG, Mungall BA, Greengard O, Niewiesk S, Moscona A.

J Virol. 2009 Jul;83(13):6900-8. doi: 10.1128/JVI.00475-09. Epub 2009 Apr 22.

45.

Kinetic dependence of paramyxovirus entry inhibition.

Porotto M, Yokoyama CC, Orefice G, Kim HS, Aljofan M, Mungall BA, Moscona A.

J Virol. 2009 Jul;83(13):6947-51. doi: 10.1128/JVI.00416-09. Epub 2009 Apr 15.

46.

Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy.

Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, Aljofan M, Whitt M, Glickman F, Moscona A.

J Virol. 2009 May;83(10):5148-55. doi: 10.1128/JVI.00164-09. Epub 2009 Mar 4.

47.

Global transmission of oseltamivir-resistant influenza.

Moscona A.

N Engl J Med. 2009 Mar 5;360(10):953-6. doi: 10.1056/NEJMp0900648. Epub 2009 Mar 2. No abstract available.

48.

Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.

Peters PH, Moscona A, Schulman KL, Barr CE.

Medscape J Med. 2008 Jun 4;10(6):131.

49.

Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus.

Aljofan M, Porotto M, Moscona A, Mungall BA.

J Virol Methods. 2008 Apr;149(1):12-9. doi: 10.1016/j.jviromet.2008.01.016. Epub 2008 Mar 4.

50.

CSI microbiology: emerging pathogens and a staged strategy for detection and discovery.

Moscona A.

J Infect Dis. 2007 Dec 15;196(12):1727-8. doi: 10.1086/524313. No abstract available.

PMID:
18190250

Supplemental Content

Loading ...
Support Center